Streetbeat News

Regulatory

VIEW

View announces plans for a reverse stock split to ensure full compliance with Nasdaq listing rules. The company will seek stockholder approval at its 2023 annual meeting, with potential split ratios ranging from 40-for-1 to 60-for-1.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 9:19 pm

LUNAUSD

Terra (CRYPTO: LUNA) founder Do Kwon's bail request has been approved by the Montenegro court, following the annulment of a previous approval by a higher court. Kwon and former Terra executive Han Chang-joon were arrested for allegedly attempting to travel with forged documents. Kwon's cryptocurrency enterprise collapsed last year, leading to extradition requests from South Korea and the U.S.

Portfolio Pulse from Murtuza Merchant

June 05, 2023 | 8:49 pm

CRH

MLM

VMC

Dublin-based construction supply company CRH plc is undervalued compared to its rivals Martin Marietta Materials (NYSE:MLM) and Vulcan Materials (NYSE:VMC), according to Street Sheet. CRH is expected to benefit from $2 trillion in spending from recent US government initiatives, and its primary stock market listing is moving to the US.

Portfolio Pulse from Anthony Noto

June 05, 2023 | 8:41 pm

AROW

Arrow Financial Corp has submitted a remediation plan to Nasdaq on June 1 to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 8:29 pm

ATRO

Astronics Corporation has filed a $150 million universal shelf registration statement with the SEC, allowing the company to potentially offer and sell various securities in the future.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 8:26 pm

MSFT

Microsoft reports that the impact associated with MO571683 and EX571516 has reoccurred and they are currently investigating the cause.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 8:19 pm

PYPD

PolyPid has received a 180-day extension to regain compliance with Nasdaq's minimum bid requirement and will transfer its listing to the Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 8:05 pm

GLPG

Galapagos will present its CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data for CD19 CAR-T candidate, GLPG5201, at the EHA 2023 Congress.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 8:04 pm

ERAS

Erasca has provided an update on its clinical program for ERK inhibitor ERAS-007, refining its pipeline and focusing on the development of the drug candidate for cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 8:03 pm

MREO

RARE

Ultragenyx and Mereo BioPharma report positive data from the ongoing Phase 2/3 Orbit study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI). The treatment showed significant improvements in bone formation and density, with no serious adverse events observed.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 8:03 pm